The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

Merck & Co., Inc. MRK presented encouraging five-year survival data on its PD-L1 inhibitor, Keytruda in patients with advanced non-small cell lung cancer (NSCLC) at the annual meeting of American ...

Merck’s attempt to use Lynparza to boost Keytruda in metastatic non-small cell lung cancer has come up short with a second pivotal trial failure. Replacing the chemotherapy pemetrexed with Lynparza ...

CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...

Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.

The Phase III trial named Harmoni-2 was held in China, in conjunction with Summit's partner Akeso. In the trial, Ivonescimab and Keytruda were administered as a monotherapy to patients with locally ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

New approval in Japan for KEYTRUDA regimen in the perioperative setting for certain patients with NSCLC based on results from KEYNOTE-671 Approval in Japan also demonstrates KEYTRUDA’s important role ...

Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance Lynparza (olaparib) for certain ...

Bristol-Myers Squibb (BMS) stumbled last month when its immunotherapy treatment Opdivo failed in a crucial first-line non-small cell lung cancer (NSCLC) trial – now rival Merck looks set to capitalise ...